Treatment Shortening of MDR-TB Using Existing and New Drugs

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
The purpose of this study is to compare the efficacy of a \'new treatment regimen including delamanid, linezolid, levofloxacin, and pyrazinamide for nine or twelve months (investigational arm)\' and \'the standard treatment regimen including injectables for 20 to 24 months (control arm)\' for treating fluoroquinolone-sensitive multidrug-resistant tuberculosis.
Epistemonikos ID: d5279780ab4919368a21fc970b70162934b1164c
First added on: May 12, 2024